Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927383 | 1.00 | NPSR1 (0.47) | NPSR1KMT2AHSD11B1ATMPOLB | |
| SCHEMBL1927386 | 0.88 | NPSR1 (0.47) | NPSR1KMT2AHSD11B1ATMPOLB | |
| SCHEMBL1925514 | 0.86 | NPSR1 (0.47) | NPSR1KMT2AATMPOLBL3MBTL1 | |
| SCHEMBL1926172 | 0.82 | NPSR1 (0.47) | NPSR1KMT2AHSD11B1ATML3MBTL1 | |
| SCHEMBL1925500 | 0.81 | NPSR1 (0.47) | NPSR1KMT2AHSD11B1POLBL3MBTL1 | |
| SCHEMBL1925891 | 0.81 | NPSR1 (0.49) | NPSR1KMT2AHSD11B1ATML3MBTL1 | |
| SCHEMBL1925249 | 0.81 | NPSR1 (0.47) | NPSR1KMT2AHSD11B1ATMPOLB | |
| SCHEMBL1925232 | 0.79 | NPSR1 (0.46) | NPSR1KMT2AHSD11B1POLBL3MBTL1 | |
| SCHEMBL1927772 | 0.78 | NPSR1 (0.53) | NPSR1KMT2APOLBL3MBTL1TDP1 | |
| SCHEMBL1926047 | 0.78 | NPSR1 (0.40) | NPSR1KMT2AHSD11B1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011071947-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | claimed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | claimed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2509941-A2 | N-ACYLATED HYDROXYLAMINE DERIVATIVES AND O-ACYLATED HYDROXYLAMINE DERIVATIVES | The Johns Hopkins University (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071947-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071951-A2 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-16 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | NPSR1 1092/4885KMT2A 580/4885HSD11B1 323/4885 |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | TNNI3, TNNT2, TNNC1 | NPSR1 309/4885KMT2A 1413/4885HSD11B1 342/4885 |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | NPSR1 1092/4885KMT2A 580/4885HSD11B1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.